Updated Jul. 24, 2013 at 10:33 a.m.

Premium Lock Orphan disease drug from BioCryst a winner? Too early to tell

Published: 2013-07-23 19:01:00
Updated: 2013-07-24 10:33:25

BioCryst's BCX4161 BioCryst's BCX4161

BioCryst experimental drug for hereditary angiodema has traits setting it apart from other HAE drugs but it's got a long way to go before it reaches patients. Read more about the company's plans....

Read More
Read More

WRAL TechWire any time: Twitter, Facebook

Copyright 2014 WRAL TechWire. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Best of TechWire Insider

Techwire Inside Partners

OUR INSIDERS

Dr. Mike Walden
Tech economy
Frank Vinluan
Life science
Vivek Wadhwa
Commentary
Scroll